Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Treasury Shares (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Treasury Shares for 11 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares fell 6.33% to $5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, down 6.33% year-over-year, with the annual reading at $5.2 million for FY2025, 6.33% down from the prior year.
  • Treasury Shares for Q4 2025 was $5.2 million at Intellia Therapeutics, down from $5.2 million in the prior quarter.
  • The five-year high for Treasury Shares was $5.7 million in Q1 2024, with the low at $442740.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $3.4 million, with a median of $4.0 million recorded in 2023.
  • The sharpest move saw Treasury Shares skyrocketed 334.88% in 2022, then decreased 6.33% in 2025.
  • Over 5 years, Treasury Shares stood at $453026.0 in 2021, then skyrocketed by 328.54% to $1.9 million in 2022, then skyrocketed by 108.19% to $4.0 million in 2023, then skyrocketed by 37.26% to $5.5 million in 2024, then dropped by 6.33% to $5.2 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $5.2 million, $5.2 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.